TCF7L2

Across TCGA pan-cancer cohorts, TCF7L2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TCF7L2’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where TCF7L2 RNA is repressed in tumor relative to normal tissue. In most cancer types TCF7L2 is over-expressed in tumor, although a few such as UCEC and THCA show the opposite, repressed pattern.

UCEC, THCA, and BRCA are the cancer types where TCF7L2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCF7L2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	−1.495	<.001	8	view →
THCA	Male	All	−0.615	<.001	8	view →
BRCA	All	III,IV	−1.188	<.001	6	view →
KICH	Female	All	−1.140	<.001	6	view →
STAD	Male	II,III,IV	+0.837	.001	6	view →
COAD	Female	All	−0.777	<.001	6	view →
LIHC	All	II,III,IV	+0.595	<.001	6	view →
LUSC	All	All	−0.547	<.001	5	view →
LUAD	Female	All	−0.499	<.001	5	view →
CHOL	All	All	+1.025	.001	3	view →
ESCA	All	All	+1.383	.009	2	view →
PAAD	All	All	+0.835	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TCF7L2–UCEC

Open the UCEC breakdown →